A Raleigh company that sells a blood test to measure patients' risk for heart disease is reviving plans for an initial public offering of stock.
LipoScience wants to raise $86.25 million in an IPO, the company disclosed in a Securities and Exchange Commission filing.
The company first filed IPO plans in 2002, but scrapped them after failing to attract enough interest on Wall Street. This time, LipoScience officials are hoping that having a few more years of steady revenue growth will help sell their story to investors. They're also counting on renewed interest in IPOs.
Founded in 1994 based on research at N.C. State University, LipoScience's main product is the NMR LipoProfile, a diagnostic test that checks the levels of bad cholesterol in the blood.